Argenx announced positive topline results from the company’s Phase III ADAPT clinical trial of efgartigimod for myasthenia gravis.

Allergan’s Botox was given the green light from the U.S. FDA to treat pediatric patients with lower limb spasticity.

Jacobus Pharmaceutical Co. Inc. won U.S. approval for the first drug to treat children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.

Taking caffeine before exercise could improve performance during a broad range of exercise tasks, according to a new review of past research.

PhaseBio Pharmaceuticals’ antiplatelet drug PB2452 received Breakthrough Therapy designation from the U.S. FDA.